MINNEAPOLIS, MINNESOTA--(Marketwired - June 24, 2013) - DiaMedica (TSX VENTURE:DMA), a clinical stage biopharmaceutical company, today provided an update on the ongoing clinical trial program for ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results